Differential sensitivities of the vascular KATP channel to various PPAR activators
Authors:
- 13 March 2013
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 85 (10) , 1495-1503
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Rosiglitazone selectively inhibits KATPchannels by acting on the KIR6 subunitBritish Journal of Pharmacology, 2012
- PPAR-α effects on the heart and other vascular tissuesAmerican Journal of Physiology-Heart and Circulatory Physiology, 2003
- Hypercapnic Acidosis Activates K ATP Channels in Vascular Smooth MusclesCirculation Research, 2003
- Novel selective small molecule agonists for peroxisome proliferator-activated receptor δ (PPARδ)—synthesis and biological activityBioorganic & Medicinal Chemistry Letters, 2003
- Protein kinase C modulation of recombinant ATP‐sensitive K+ channels composed of Kir6.1 and/or Kir6.2 expressed with SUR2BThe Journal of Physiology, 2002
- Rosiglitazone: an agent from the thiazolidinedione class for the treatment of type 2 diabetes.2001
- Rosiglitazone treatment of patients with extreme insulin resistance and diabetes mellitus due to insulin receptor mutations has no effects on glucose and lipid metabolismJournal of Internal Medicine, 2001
- Actos (pioglitazone): a new treatment for type 2 diabetesHospital Medicine, 2001
- Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: A randomized, placebo-controlled studyClinical Therapeutics, 2000
- Rosiglitazone approved for treatment of type 2 diabetes.American Journal of Health-System Pharmacy, 1999